Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Harmony Biosciences Holdings (HRMY) Net Income (2019 - 2025)

Harmony Biosciences Holdings' Net Income history spans 7 years, with the latest figure at $22.5 million for Q4 2025.

  • For Q4 2025, Net Income fell 66.1% year-over-year to $22.5 million; the TTM value through Dec 2025 reached $158.7 million, down 2.25%, while the annual FY2025 figure was $158.7 million, 2.25% down from the prior year.
  • Net Income for Q4 2025 was $22.5 million at Harmony Biosciences Holdings, down from $50.9 million in the prior quarter.
  • Across five years, Net Income topped out at $87.9 million in Q3 2022 and bottomed at -$37.8 million in Q4 2022.
  • The 5-year median for Net Income is $28.0 million (2023), against an average of $29.0 million.
  • The largest YoY upside for Net Income was 52385.19% in 2021 against a maximum downside of 603.93% in 2021.
  • A 5-year view of Net Income shows it stood at $22.7 million in 2021, then crashed by 266.62% to -$37.8 million in 2022, then skyrocketed by 170.3% to $26.6 million in 2023, then soared by 149.26% to $66.3 million in 2024, then tumbled by 66.1% to $22.5 million in 2025.
  • Per Business Quant, the three most recent readings for HRMY's Net Income are $22.5 million (Q4 2025), $50.9 million (Q3 2025), and $39.8 million (Q2 2025).